It has been found that treatment of cancer cells with rapamycin or rapalogs can cause the activation of PI3K/Akt through the S6K1-IRS negative feedback mechanism, reducing the apoptotic potential in cancer cells [46,50,58]. Here, RPS6KB1 is linked to cancer.